Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of Segment Information

The following table provides information about the Company's single operating segment which includes significant expenses by function along with significant non-cash expense items.

	Year Ended December 31,
	2024			2023
Revenue:
Collaboration and license revenue		2,816			21,049
Operating expenses:
Research and development:
Personnel expenses		31,742			24,165
Laboratory supplies, research materials and studies		31,468			30,101
Clinical studies		19,245			10,214
Facility-related and other		16,669			16,298
Stock-based compensation		4,846			2,876
Depreciation expense		3,380			4,499
General and administrative:
Personnel expenses		10,900			9,065
Legal and professional fees		7,380			7,119
Facility-related and other		6,576			6,976
Stock-based compensation		4,703			2,332
Depreciation Expense		728			862
Loss from operations		(134,821	)		(93,458	)
Other (expense) income:
Interest and other income, net		12,065			7,999
Interest expense		(3,653	)		(3,759	)
Loss on extinguishment of debt		(1,090	)		-
Net Loss		(127,499	)		(89,218	)